Etanercept: Efficacy and safety

• Published in: Journal of the European Academy of Dermatology and Venereology 2009-04, Vol.23 (4), p.402-405
• Main Authors: Jiménez-Puya, R, Gómez-García, F, Amorrich-Campos, V, Moreno-Giménez, JC
• Format: Article
• Language: English
• Subjects: efficacy; Etanercept; Humans; Immunoglobulin G - administration & dosage; Immunoglobulin G - therapeutic use; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Longitudinal Studies; Mycobacterium; psoriasis; Psoriasis - drug therapy; Psoriasis - pathology; Receptors, Tumor Necrosis Factor - administration & dosage; Receptors, Tumor Necrosis Factor - therapeutic use; Retrospective Studies; safety
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/j.1468-3083.2008.03063.x

Objective  To evaluate the efficacy and safety of etanercept in the treatment of patients with moderate to severe plaque psoriasis. Methods  An observational, longitudinal, and retrospective study involving two groups of dose of treatment with etanercept (50 vs. 100 mg/week). The selected patients presented moderate to severe plaque psoriasis, and they had received treatment with the mentioned drug. A total of 58 patients were included in the study. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), body surface area (BSA) and physician's global assessment (PGA) in weeks 8, 16, 24, 32, 40 and 48. Results  A statistically significant improvement was observed in the PASI, BSA and PGA indexes after 24 and 48 weeks of therapy. As for PASI, and after 48 weeks of treatment, PASI 50, 75 and 90 were 100.0%, 92.3% and 69.2%, respectively. In our series, etanercept 50 mg/week reached the same results after 48 weeks as etanercept 100 mg/week, though the initial response was faster in the last group. The PASI, BSA and PGA indexes diminished significantly with the treatment, though without statistically significant differences between both groups. As for the safety, etanercept was well tolerated, and no serious adverse events were recorded. There were no cases of tuberculosis or opportunistic infections. Conclusions  Our study confirms the efficacy and safety outcomes of the clinical trials of etanercept in psoriasis with both doses of treatment. As for the safety, etanercept was well tolerated, and all the recorded adverse events coincided with the known potential side‐effects of treatment. Conflicts of interest None declared